Cholangiocarcinoma is a diverse malignancy that arises from the
epithelium of the bile ducts and features differentiated cholangiocytes.
CCA is a very challenging malignancy with low survival rates,
inconsistent genetic profile, low response to chemotherapy, high
recurrence rate and, although fairly well manageable with surgical
resection, the majority of patients are primarily presenting at a stage
of irresectable disease. David Winkler, Vijayanand Rajendran and
Mohamed El Malt of Europital recommends why patients should
enter clinical trials whenever available.